Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Feb 8;18(5):265-71.
doi: 10.1016/j.rpor.2012.12.006. eCollection 2013.

Radiobiological comparison of two radiotherapy treatment techniques for high-risk prostate cancer

Affiliations

Radiobiological comparison of two radiotherapy treatment techniques for high-risk prostate cancer

Trinitat García Hernández et al. Rep Pract Oncol Radiother. .

Abstract

Background: To make a radiobiological comparison, for high risk prostate cancer (T3a, PSA > 20 ng/ml or Gleason > 7) of two radiotherapy treatment techniques. One technique consists of a treatment in three phases of the pelvic nodes, vesicles and prostate using a conventional fractionation scheme of 2 Gy/fraction (SIMRT). The other technique consists of a treatment in two phases that gives simultaneously different dose levels in each phase, 2 Gy/fraction, 2.25 Gy/fraction and 2.5 Gy/fraction to the pelvic nodes, vesicles and prostate, respectively (SIBIMRT).

Materials and methods: The equivalent dose at fractionation of 2 Gy (EQD2), calculated using the linear quadratic model with α/β prostate = 1.5 Gy, was the same for both treatment strategies. For comparison the parameters employed were D95, mean dose and Tumour Control Probabilities for prostate PTV and D15, D25, D35, D50, mean dose and Normal Tissue Complication Probabilities for the rectum and bladder, with physical doses converted to EQD2. Parameters were obtained for α/β prostate = 1.5, 3 and 10 Gy and for α/β oar = 1, 2, 3, 4, 6 and 8.

Results: For prostate PTV, both treatment strategies are equivalent for α/β prostate = 1.5 Gy but for higher α/β prostate, EQD2 and TCP, decrease for the SIBIMRT technique. For the rectum and bladder when α/β oar ≤ 2 Gy, EQD2 and NTCP are lower for the SIMRT technique or equal in both techniques. For α/β oar ≥ 2-3 Gy, EQD2 and NTCP increase for the SIMRT treatment.

Conclusions: A comparison between two radiotherapy techniques is presented. The SIBIMRT technique reduces EQD2 and NTCP for α/β oar from 2 to 8 Gy.

Keywords: Equivalent dose at fractionation of 2 Gy (EQD2); NTCP; Prostate; Radiobiology; Simultaneous integrated boost.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Isodose curves in a transverse and coronal plane for the SIMRT and the SIBIMRT techniques.
Fig. 2
Fig. 2
Mean rectum EQD2 15, EQD2 25, EQD2 35 and EQD2 50 for SIMRT and SIBIMRT techniques and for α/βoar values of 1, 2 (a) 3, 4 (b) and 6, 8 Gy (c). The black and grey colours correspond to the lower and higher α/βoar values in each subfigure. For each EQD2 the p value is indicated in the graph. (d) Mean rectum EQD2 for SIMRT and SIBIMRT techniques for α/βoar = 1, 2, 3,4, 6 and 8 Gy.
Fig. 3
Fig. 3
Mean bladder EQD2 15, EQD2 25, EQD2 35, EQD2 50 for SIMRT and SIBIMRT techniques and for α/βoar values of 1, 2 (a) 3, 4 (b) and 6, 8 (c). The black and grey colours correspond to the lower and higher α/βoar values in each subfigure. For each EQD2 the p value is indicated in the graph. Mean bladder EQD2 for SIMRT and SIBIMRT techniques for α/βoar = 1, 2, 3, 4, 6 and 8 Gy.
Fig. 4
Fig. 4
Rectum (a) and bladder (b) NTCP versus α/βoar with α/βoar = 1, 2, 3, 4, 6 and 8 Gy. For each NTCP the p value is indicated in the graph.

Similar articles

Cited by

References

    1. Ceylan C., Kucuk N., Bas Ayata H., Guden M., Engin K. Dosimetric and physical comparisonvof IMRT and CyberKnife plans in the treatment of localized prostate cancer. Rep Pract Oncol Radiother. 2010;15(6):181–189. - PMC - PubMed
    1. Wang J.Z., Guerrero M., Li X.A. How low is the a/b ratio for prostate cancer? Int J Radiat Oncol Biol Phys. 2003;55:194–203. - PubMed
    1. Fowler J., Chappell R., Ritter M. Is a/b for prostate tumors really low? Int J Radiat Oncol Biol Phys. 2001;50:1021–1031. - PubMed
    1. Dasu A. Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials? Clin Oncol (R Coll Radiol) 2007;19:289–301. - PubMed
    1. Ritter M., Forman J., Kupelian P., Lawton C., Petereit D. Hypofractionation for Prostate Cancer. Cancer J. 2009;15(1):1–6. - PMC - PubMed